YUHAN CORPORATION
Financials
Valuation Metrics
YUHAN CORPORATION's Market Cap is ₩5.6T. At end of 2025 it was ₩8.4T. Ranked #102 of 2,420 in KR market (top 4%), #93 of 781 on KOSPI (top 12%), #7 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 5.58T KRW | KR#102/2,420 Sec#7/231 |
| Revenue | 2.28T KRW | KR#234/2,420 Sec#4/231 |
| Net Income | 222.72B KRW | KR#133/2,420 Sec#5/231 |
| Total Assets | 3.33T KRW | KR#225/2,420 Sec#6/231 |
| Net Assets | 2.47T KRW | KR#156/2,420 Sec#4/231 |
| Employees | 2,117 | KR#133/2,420 Sec#6/231 |
| Value | ||
| P/E | 25.06x | KR#1,240/2,420 Sec#73/231 |
| P/B | 2.26x | KR#1,972/2,420 Sec#149/231 |
| PEG | 0.14x | KR#479/2,420 Sec#28/231 |
| P/S | 2.45x | KR#1,885/2,420 Sec#111/231 |
| EV/EBITDA | 44.45x | KR#1,304/2,420 Sec#83/231 |
| FCF Yield | 0.12% | KR#1,209/2,420 Sec#92/231 |
| Profitability | ||
| ROE | 9.01% | KR#699/2,420 Sec#49/231 |
| ROA | 6.69% | KR#552/2,420 Sec#44/231 |
| Op. Margin | 5.42% | KR#910/2,420 Sec#68/231 |
| Revenue Growth | 5.40% | KR#1,175/2,420 Sec#115/231 |
| Earnings Growth | 178.66% | KR#261/2,420 Sec#16/231 |
| Financial Health | ||
| Debt Ratio | 34.77% | KR#687/2,420 Sec#83/231 |
| Total Debt | 349.53B KRW | KR#370/2,420 Sec#18/231 |
| FCF | 6.63B KRW | KR#832/2,420 Sec#54/231 |
| Cash | 427.95B KRW | KR#158/2,420 Sec#2/231 |
| Current Ratio | 2.27x | KR#766/2,420 Sec#91/231 |
| Net Debt/EBITDA | -0.63x | KR#461/2,420 Sec#26/231 |
| Dividend | ||
| Div. Yield | 0.80% | KR#1,156/2,420 Sec#71/231 |
| Div. Growth | 20.00% | KR#437/2,420 Sec#23/231 |
| Performance | ||
| 1Y Return | -37.61% | KR#1,871/2,420 Sec#161/231 |
| 1M Return | -7.31% | KR#2,103/2,420 Sec#191/231 |
| From 52W High | -42.11% | KR#1,118/2,420 Sec#80/231 |
| 1Y MDD | -46.88% | KR#858/2,420 Sec#70/231 |
| Trading | ||
| Volume | 153,528 shares | KR#757/2,420 Sec#64/231 |
| Trading Value | 11.56B KRW | KR#297/2,420 Sec#27/231 |
| Foreign Own. | 21.26% | KR#209/2,420 Sec#9/231 |
| Per Share | ||
| EPS | 2,985 KRW | KR#342/2,420 Sec#22/231 |
| BPS | 33,119 KRW | KR#343/2,420 Sec#22/231 |
Company Info
Established in 1926 and listed on the securities market in 1962, the company is a leading pharmaceutical firm, with 14 companies under its umbrella, including a subsidiary slated for KOSDAQ listing in 2025. Its primary business is the manufacturing and sale of pharmaceuticals and chemical products, including key products like Leclaza. The company is building an innovative network by adopting AI and big data for new drug development, collaborating with global pharmaceutical companies, and conducting joint R&D with bio-ventures and universities. The company is headquartered in Dongjak-gu, Seoul.